© 2019 Genprex Inc. All Rights Reserved.
AUSTIN, Texas, April 16, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, today announced a clinical and corporate update.
AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company's President.
AUSTIN, Texas, April 6, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference
AUSTIN, Texas, April 4, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the closing of its initial public offering on April 3, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price
AUSTIN, Texas, March 29, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock
AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ -- Genprex, Inc., ("Genprex") a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.
AUSTIN, TX, July 21, 2017 – Genprex, Inc. a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
– TUSC2+PD-1 blockade demonstrates significantly greater anti-tumor effect compared to PD-1 blockade alone –
– TUSC2+PD-1 blockade increases survival in mice and elevates innate immune system activity, including upregulation of natural killer cells and cytotoxic T cells –
Genprex, Inc., a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, today announced that Julien Pham, MD, the Company’s Chief Operating Officer, is scheduled to present a corporate overview at two upcoming healthcare investor conferences.
Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®).